- |||||||||| Promacta (eltrombopag) / Novartis
Enrollment closed, Enrollment change, Trial primary completion date: Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients (clinicaltrials.gov) - Feb 2, 2017 P2, N=19, Active, not recruiting, Active, not recruiting --> Terminated; slow accrual Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Jun 2013 --> May 2019
- |||||||||| Promacta (eltrombopag) / Novartis
Trial completion, Trial initiation date, Trial primary completion date: Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 2, 2017 P2, N=12, Completed, Recruiting --> Active, not recruiting | N=50 --> 19 | Trial primary completion date: Jun 2013 --> May 2019 Active, not recruiting --> Completed | Initiation date: May 2009 --> Jan 2009 | Trial primary completion date: Jan 2014 --> Sep 2015
- |||||||||| tranexamic acid oral / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders (clinicaltrials.gov) - Jan 31, 2017 P4, N=249, Completed, Trial primary completion date: Dec 2016 --> Apr 2017 Not yet recruiting --> Completed | N=149 --> 249 | Initiation date: Jun 2009 --> Oct 2009 | Trial primary completion date: Jun 2010 --> Mar 2014
- |||||||||| RiaSTAP (fibrinogen concentrate (human)) / CSL Behring
Trial completion, Surgery: Fibrinogen as an Alternative to FFP in Aortic Surgery. (clinicaltrials.gov) - Jan 31, 2017 P4, N=20, Completed, Trial primary completion date: Dec 2016 --> Dec 2018 Recruiting --> Completed
- |||||||||| dinaciclib (MK-7965) / Merck (MSD)
Enrollment closed, Combination therapy: Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 30, 2017 P1, N=40, Active, not recruiting, Active, not recruiting --> Completed Suspended --> Active, not recruiting
- |||||||||| Xyntha (moroctocog alfa) / Pfizer
Enrollment closed, Trial primary completion date, Adverse events: Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) - Jan 24, 2017 P=N/A, N=140, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Oct 2016
- |||||||||| aspirin / Generic mfg., hydroxyurea / Generic mfg.
Trial completion, Trial primary completion date: Primary Thrombocythaemia 1 Trial (clinicaltrials.gov) - Jan 18, 2017 P=N/A, N=1398, Completed, Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2014 Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016
- |||||||||| Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment closed, Enrollment change: Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (clinicaltrials.gov) - Jan 18, 2017 P2, N=21, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Apr 2024 --> Nov 2016 Recruiting --> Active, not recruiting | N=86 --> 21
- |||||||||| bortezomib / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - Jan 13, 2017 P2, N=10, Completed, Recruiting --> Active, not recruiting | N=53 --> 40 | Trial primary completion date: Feb 2017 --> Sep 2018 Recruiting --> Completed | N=30 --> 10 | Trial primary completion date: Dec 2017 --> Oct 2016
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion, Surgery: Use of Activated Recombinant FVII in Spinal Surgery (clinicaltrials.gov) - Jan 12, 2017 P2, N=50, Completed, Recruiting --> Completed | N=30 --> 10 | Trial primary completion date: Dec 2017 --> Oct 2016 No longer recruiting --> Completed
- |||||||||| Phase classification: MRA With Feraheme in HHT (clinicaltrials.gov) - Jan 12, 2017
P1, N=10, Recruiting, N=300 --> 176 | Recruiting --> Terminated | Trial primary completion date: Nov 2016 --> Jul 2016; Business Decision Phase classification: P=N/A --> P1
- |||||||||| NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion: Trial of NovoSeven (clinicaltrials.gov) - Jan 11, 2017 P4, N=42, Completed, Recruiting --> Active, not recruiting | N=300 --> 168 | Trial primary completion date: Jun 2024 --> Jun 2017 Recruiting --> Completed
|